Use of a chlorhexidine-impregnated patch does not decrease the incidence of bacterial colonization of femoral nerve catheters: a randomized trial
Kristopher M Schroeder, Robert A Jacobs, Christopher Guite, Kyle Gassner, Brooke Anderson, Melanie J Donnelly, Kristopher M Schroeder, Robert A Jacobs, Christopher Guite, Kyle Gassner, Brooke Anderson, Melanie J Donnelly
Abstract
Purpose: Femoral nerve catheter (FNC) insertion is commonly performed for postoperative analgesia following total knee arthroplasty (TKA). A wide range of rates has been reported relating to the bacterial colonization of catheters complicating FNC insertion. The BIOPATCH® is a chlorhexidine (CHG) impregnated patch designed to inhibit bacterial growth for days. The BIOPATCH has proven to be effective at decreasing bacterial colonization in epidural and vascular catheters. We hypothesized that the BIOPATCH would be effective at decreasing the rates of FNC bacterial colonization.
Methods: Following Institutional Review Board approval and written informed consent, 100 patients scheduled for TKA were prospectively enrolled in the study. Patients at elevated risk for infection were excluded from analysis. Femoral nerve catheters were inserted and tunneled under sterile conditions using ultrasound guidance following CHG skin cleansing. Participants were then randomized either to have the BIOPATCH applied to the catheter exit site or not to have the patch applied. All patients received pre/postoperative antibiotic therapy. The FNC tip and catheter exit site were cultured for bacterial growth at the conclusion of therapy.
Results: No differences were observed between groups in regards to catheter exit site. Catheter colonization was observed in three of 48 (6.3%) BIOPATCH patients and two of 47 (4.3%) non-BIOPATCH patients (risk ratio [RR] = 1.5; 95% confidence interval [CI] 0.3 to 8.4; P = 1.0). Colonization of the catheter exit site was observed in 12 BIOPATCH and 14 non-BIOPATCH patients (RR = 0.8; 95% CI 0.4 to 1.6; P = 0.65). Local skin inflammation (non-BIOPATCH 10.6% vs BIOPATCH 2.1%) and colonization of the FNC exit site by more than one type of bacteria trended towards increased values in the non-BIOPATCH group.
Conclusions: The baseline rate of bacterial colonization of FNCs is quite low in the setting of short-term use, CHG skin decontamination, ultrasound guidance, subcutaneous tunneling, and perioperative antibiotic therapy. No benefit was shown by using the BIOPATCH in this patient population. (ClinicalTrials.gov number: NCT01411891).
Figures
Source: PubMed
Prossimi studi clinici
-
Nicholas ButowskiSiren BiotechnologyNon ancora reclutamentoGlioma | Neoplasia cerebrale | Gliomi ricorrenti di alto gradoStati Uniti
-
State University of New York at BuffaloNon ancora reclutamentoCoinvolgimento del pazienteStati Uniti
-
Poitiers University HospitalNon ancora reclutamento
-
Assistance Publique - Hôpitaux de ParisNon ancora reclutamentoAnemia falciforme | Crisi vaso-occlusiva
-
University of California, IrvineReclutamentoCancro al cervello | Cancro al SNC | Cancro del sistema nervoso | Metastasi del Cancro al CervelloStati Uniti
-
Qualia Life SciencesReclutamento
-
Guangdong Raynovent Biotech Co., LtdNon ancora reclutamento
-
The Hong Kong Polytechnic UniversityWu Jieh Yee Charitable FoundationReclutamentoAdulti | Assistenza digitale per ipovedenti | Deficit VisiviHong Kong
-
Shanghai General Hospital, Shanghai Jiao Tong University...Non ancora reclutamentoAdenocarcinoma duttale pancreatico (PDAC)
-
Sun Yat-sen UniversityNon ancora reclutamentoSmettere di fumare | Agente AI | Early-Stage Cancer
-
Affiliated Hospital of Nantong UniversityNon ancora reclutamento
-
AIMEDBIOBoehringer IngelheimNon ancora reclutamentoTumori solidiFrancia, Giappone, Corea del Sud, Stati Uniti, Australia
